Analysis of serum interleukin-27 and interleukin-35 concentrations in patients with Guillain-Barré syndrome

IL-27 might be pathogenic, whereas IL-35 be protective in GBS. Additionally, serum IL-35 concentrations may be important biomarkers for the severity and outcomes of AMAN.